Homepage
Author:
AC Immune SA
Posted Date:
April 7, 2026
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
AC Immune SA
April 7, 2026
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
AC Immune SA
March 19, 2026
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
AC Immune SA
March 13, 2026
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
AC Immune SA
March 5, 2026
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
AC Immune SA
February 24, 2026
